Counselors in Estherville, IA Accepting Medicare

5 Counselors found. Showing 1 - 5

Amy J Nissen, CADC Counselor - Addiction (Substance Use Disorder) Medicare: Not Enrolled in Medicare Practice Location: 1820 Central Ave, Estherville, IA 51334 Phone: 800-592-0180    Fax: 712-566-5229

Emili Lair Counselor - Professional Medicare: Not Enrolled in Medicare Practice Location: 1797 340th Ave, Estherville, IA 51334 Phone: 712-357-8742

Amanda Olson, LMHC Counselor - Mental Health Medicare: Not Enrolled in Medicare Practice Location: 508 W Central Ave Ste B, Estherville, IA 51334 Phone: 800-592-0180

Madison Gabrielle Wagner, LMHC, NCC Counselor - Mental Health Medicare: Not Enrolled in Medicare Practice Location: 1820 Central Ave, Estherville, IA 51334 Phone: 800-592-0180

Suzan Marie Loverink, LMHC Counselor - Mental Health Medicare: Medicare Enrolled Practice Location: 508 W Central Ave, Ste B, Estherville, IA 51334 Phone: 800-592-0180    Fax: 712-566-5229

News Archive

Experts demand more funds to stop the spread of bird flu

At a meeting in Beijing to whip up funds for the global fight against bird flu, the European Union has raised its contribution to the fund by $20 million taking their total commitment to $120 million, but other contributions appear to be thin on the ground.

U.S. FDA agrees to the study design for cardiovascular outcomes trial of alogliptin

Takeda Pharmaceutical Company Limited ("Takeda") and Takeda Global Research & Development Center, Inc., a wholly owned United States (U.S.) subsidiary, today jointly announced that the latter has received notification that the U.S. Food and Drug Administration (FDA) has agreed to the study design for a cardiovascular (CV) outcomes trial titled EXAMINE (EXamination of CArdiovascular OutcoMes: AlogliptIN vs. Standard of CarE in Patients with Type 2 Diabetes Mellitus and Acute Coronary Syndrome) for alogliptin, a selective dipeptidyl peptidase IV inhibitor under investigation for the treatment of type 2 diabetes as an adjunct to diet and exercise.

Finding could provide targets for diagnosis, prognosis, therapy of prostate cancer

Researchers led by Dr. Shiv Srivastava from the Center for Prostate Disease Research (CPDR), Uniformed Services University of the Health Sciences (USU), report the groundbreaking discovery of the ETS-Related Gene (ERG) as one of the frequent proto-oncogene overexpressions in prostate cancer cells.

GILZ protein may have big role in making more bone and less fat

A small protein may have a big role in helping you make more bone and less fat, researchers say. "The pathways are parallel, and the idea is if you can somehow disrupt the fat production pathway, you will get more bone," says Dr. Xingming Shi, bone biologist at the Medical College of Georgia Institute of Molecular Medicine and Genetics.

Study refocuses on how neuroblastoma tumors evolve in response to medicine and other factors

An extensive genomic study of the childhood cancer neuroblastoma reinforces the challenges in treating the most aggressive forms of this disease. Contrary to expectations, the scientists found relatively few recurrent gene mutations—mutations that would suggest new targets for neuroblastoma treatment. Instead, say the researchers, they have now refocused on how neuroblastoma tumors evolve in response to medicine and other factors.

Read more Medical News

› Verified 8 days ago